Observational studyInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Introduction of DNA-HPV test in the Brazilian cervical cancer screening program: When the idea is good but does not fit the budget.
Observational study in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the financial applicability of the DNA-HPV test for cervical cancer screening in a developing country like Brazil.
methodsThis was a retrospective, observational study based on documentary data, conducted to assess the cost-effectiveness of cervical cancer screening strategies in Brazil. The study used national cervical cancer screening data collected between January 1 and December 31, 2020 for women between 25 and 64 years old, performing a cost-effectiveness assessment of two different screening tests. No sensitivity analysis was conducted due to the descriptive nature of this preliminary cost assessment.
resultsBased on the cervical smear, the Brazilian protocol has an estimated cost of US$117.5 million. In contrast, when using the HPV DNA test, the estimated cost is US$1.39 billion.
conclusionThe current use of the cervical smear is the least expensive and the only one that aligns with Brazil's financial resources allocated to health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.